Search research articles
Contact Us
Filters
Showing results (161-170 of 184) with videos related to
Page
of 19
Sort By:
Journal of Neuroendocrinology
|
October 20, 2021
ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours
Rodney J Hicks, Clarisse Dromain, Wouter W de Herder, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 13, 2025
Dosimetry of [<sup>177</sup>Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial
Lisa Bodei, Marta Cremonesi, Mahila Ferrari, et al.
Brachytherapy
|
April 7, 2021
ACR-ABS-ACNM-ASTRO-SIR-SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies
Kelvin Hong, Olaguoke Akinwande, Lisa Bodei, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 9, 2020
The Future of Nuclear Medicine, Molecular Imaging, and Theranostics
Wolfgang A Weber, Johannes Czernin, Carolyn J Anderson, et al.
The Lancet. Oncology
|
July 1, 2024
Imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
Salomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 23, 2024
First-in-human imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate
Salomon Tendler, Mark P Dunphy, Matthew Agee, et al.
The Lancet. Oncology
|
November 18, 2021
<sup>177</sup>Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Jonathan R Strosberg, Martyn E Caplin, Pamela L Kunz, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 2, 2026
Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers
Salomon Tendler, Roberto De Gregorio, Paul Balderes, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
November 18, 2017
The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression
Pier Luigi Filosso, Mark Kidd, Matteo Roffinella, et al.
Neuroendocrinology
|
July 24, 2025
Loss of DAXX/ATRX Protein Expression Results in Ischemia Resistance and Radiation Sensitivity in Pancreatic Neuroendocrine Tumor Cells and Is Associated with Improved Response to Trans-Arterial Radioembolization
Jessica C Puzzuoli, Caleb Solivio, Gavin Yuan, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 184) with videos related to
Sort By:
Page
of 19
Journal of Neuroendocrinology
|
October 20, 2021
ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours
Rodney J Hicks, Clarisse Dromain, Wouter W de Herder, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 13, 2025
Dosimetry of [<sup>177</sup>Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial
Lisa Bodei, Marta Cremonesi, Mahila Ferrari, et al.
Brachytherapy
|
April 7, 2021
ACR-ABS-ACNM-ASTRO-SIR-SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies
Kelvin Hong, Olaguoke Akinwande, Lisa Bodei, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 9, 2020
The Future of Nuclear Medicine, Molecular Imaging, and Theranostics
Wolfgang A Weber, Johannes Czernin, Carolyn J Anderson, et al.
The Lancet. Oncology
|
July 1, 2024
Imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
Salomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 23, 2024
First-in-human imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate
Salomon Tendler, Mark P Dunphy, Matthew Agee, et al.
The Lancet. Oncology
|
November 18, 2021
<sup>177</sup>Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Jonathan R Strosberg, Martyn E Caplin, Pamela L Kunz, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 2, 2026
Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers
Salomon Tendler, Roberto De Gregorio, Paul Balderes, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
November 18, 2017
The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression
Pier Luigi Filosso, Mark Kidd, Matteo Roffinella, et al.
Neuroendocrinology
|
July 24, 2025
Loss of DAXX/ATRX Protein Expression Results in Ischemia Resistance and Radiation Sensitivity in Pancreatic Neuroendocrine Tumor Cells and Is Associated with Improved Response to Trans-Arterial Radioembolization
Jessica C Puzzuoli, Caleb Solivio, Gavin Yuan, et al.
Page
of 19